Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based biotech ...
How SMBs use threat research and MDR to build a defensive edge We speak to Director of ESET Threat Research Jean-Ian Boutin about where solutions that blend advanced technology with human expertise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results